Lv2
130 积分 2023-12-04 加入
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
1天前
待确认
On an enhanced rank‐preserving structural failure time model to handle treatment switch, crossover, and dropout
2个月前
已完结
Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification
2个月前
已完结
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
2个月前
已完结
Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)
2个月前
已完结
A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer
2个月前
已完结
P-260: Daratumumab (DARA) plus bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analyses of CASTOR and POLLUX
5个月前
已完结
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
6个月前
已完结
Department of Error
7个月前
已完结
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
7个月前
已完结
皖公网安备34019202002308
